Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-16 (Canceled)

Claim 17-25 (Canceled)

Claim 26 (Currently Amended) A method for producing an immune response against HIV-1 infection in a human comprising administering to the human an immunogenic composition comprising an intranasal or an intramuscular dosage of a recombinant adenovirus comprising an expression cassette containing a promoter, ~~part or all of~~ a nucleic acid sequence encoding the HIV-1 gp160 or gp120 polypeptide sequence and a polyadenylation signal sequence.

Claim 27 (Previously presented) The method of claim 26, further comprising the step of administering one or more intranasal or intramuscular booster dosages of the recombinant adenovirus.

Claim 28 (Previously presented) The method of claim 27, wherein the administering one or more booster dosages of the recombinant adenovirus is followed by one or more intramuscular injections of an HIV-1 antigen polypeptide dosage, wherein the antigen polypeptide is a gag polypeptide, an env polypeptide or a combination thereof.

Claim 29 (Previously presented) The method of claims 26, wherein the adenovirus is a serotype 4, a serotype 5 or a serotype 7 adenovirus.

Claim 30 (Currently Amended) The method of claim 26, wherein the expression cassette further comprises ~~part or all of~~ the coding sequence for the HIV-1 rev gene inserted in frame after the HIV-1 gp160 or gp120 sequence and before the polyadenylation signal sequence.

Claim 31 (Previously presented) The method of claim 26, wherein the HIV-1 gp160 sequence is the MN strain gp160 sequence or the LAV strain gp160 sequence.

Claim 32 (Previously presented) The method of claim 26, wherein the HIV-1 gp160 sequence is replaced by a sequence encoding the gag-pro region of HIV-1.

Claim 33 (Previously presented) The method of claim 26, wherein the intranasal dosage is about 1×10^7 pfu of virus.

Claim 34 (Previously presented) The method of claim 26, wherein the intramuscular dosage is in the range of 1×10^7 to 2×10^9 pfu of virus.

Claim 35 (Previously presented) The method of claim 27, wherein the intranasal booster dosage is in the range of 1×10^7 to 1×10^8 pfu of virus.

Claim 36 (Previously presented) The method of claim 27, wherein the intramuscular booster dosage is in the range of 1×10^{10} to 8×10^8 pfu of virus.

Claim 37 (Previously presented) The method of claim 28, wherein the antigen polypeptide dosage comprises between 200 μg and 0.5 mg of antigen polypeptide.

Claim 38 (Previously presented) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene.

Claim 39 (Previously presented) The method of claim 26, wherein the adenovirus comprises a deletion in the E3 gene and a deletion in the E1 gene or the E5 gene.

Claim 40 (Previously presented) The method of claim 26, wherein the adenovirus comprises a deletion in the E1 gene.

Claim 41 (New) The method of claim 26, wherein the HIV-1 gp120 sequence is the MN strain gp120 sequence or the LAV strain gp120 sequence.